Prevention and Treatment of Tuberculosis Among Patients Infected with Human Immunodeficiency Virus: Principles of Therapy and Revised Recommendations. Published in the Morbidity and Mortality Weekly Report October 30, 1998.
Summary Introduction Part I. Background and Scientific Rationale Part II. Recommendations - Active TB - Treatment Options - Coadministration of TB & HIV Therapy - Monthly Medical Evaluation - Drug Interaction & Absorption - Special Situations - Latent TB - Testing Among HIV Infected Individuals - Prevention Conclusions Acknowledgments References
Figure I. Recommended Management Strategies for Patients with HIV Infection and TB Table I. Annual Rates of TB Among Persons with HIV, by TST Status - Selected Years and U.S. Areas Table II. Percentage of TB Patients with Drug-Resistant Isolates, + By Drug and HIV Serostatus - U.S. 1993-1996 Table III. Post-Treatment Relapse and CD4+ T-Cell Counts Among Patients Enrolled in Prospective Studies of Regimens, by HIV Serostatus Table IV. Effects of Co-Administering Rifamycins and Protease Inhibitors on the Systemic Exposure of Each Drug Table V. Known and Predicted Effects of Co-Administering Rifamycins and NNRTI Exposure of Each Drug Table VI. Feasibility of Using Different Antiretroviral Drugs and Rifabutin Table VII. Results From Clinical Trials That Compared Rifabutin with Rifampin in Treatment for Pulmonary Tuberculosis Table VIII. Post-Treatment Relapse Rates Associated with Tuberculosis Treatment Regimens Containing Minimal or No Rifampin Among Patients Not Known to be Co-Infected with HIV Table IX. Results from Studies of TB Preventive Therapy Among Persons Co-Infected with HIV Table X. System Used to Rate the Strength of Recommendations and the Quality of Support Evidence Box 1. Components of the Medical Evaluation for HIV-Infected Patients Suspected of Having Tuberculosis Box 2. Components of the Monthly Medical Evaluation for HIV-Infected Patients Undergoing Treatment for Active TB Box 3. Components of the Baseline Medical Evaluation for TB Preventive Treatment for Patients Infected with HIV Box 4. Components of the Monthly Medical Evaluation for HIV-Infected Patients Undergoing Preventive Treatment for Latent Mycobacterium tuberculosis Infection
Physicians and other health care professionals are encouraged to consult other sources and confirm the information contained in this site because no single reference or service can take the place of medical training, education, and experience. Consumers are cautioned that this site is not intended to provide medical advice about any specific medical condition they may have or treatment they may need, and they are encouraged to call or see their physician or other health care provider promptly with any health related questions they may have.
html
pdf
selected tables
panel members
Summary